Kutikov points out that not every mass needs to be resected and that patients need to understand the risks associated with each decision they make in the treatment process.
Alexander Kutikov, MD, FACS, associate professor of Urologic Oncology, Fox Chase Cancer Center, discusses the options patients with a renal tumor have. Kutikov points out that not every mass needs to be resected and that patients need to understand the risks associated with each decision they make in the treatment process.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen